个人简介

刘晓叶，副研究员，博士生导师，青年PI。长期致力于肿瘤免疫学的研究，主要围绕以下两个方面开展深入研究，1) 免疫抑制性细胞在肿瘤微环境中的作用; 2) 免疫抑制分子在白血病中的功能。以肿瘤微环境中的免疫细胞和白血病细胞为研究对象，应用小鼠模型和临床标本、结合生物信息学、分子生物学和生物化学等技术，开展肿瘤免疫及白血病发病机制的基础与转化研究，以期为肿瘤免疫治疗提供新的思路和策略。围绕以上两个研究方向，发表了多篇高水平论文，其中第一作者/共同第一作者文章分别发表在Science Immunology、Cancer Immunology Research、Cell Reports、Journal of Clinical Investigation、Haematologica。作为共同发明人申请国际专利1项。

学习和工作经历

2025年2月-至今                   海南医科大学/海南省医学科学院       青年PI

2023年3月-2025年2月         美国得克萨斯大学西南医学中心         助理讲师

2017年2月-2023年2月         美国得克萨斯大学西南医学中心         博士后

2016年7月-2017年2月         上海交通大学医学院                          科研助理

2010年9月-2016年6月         中国科学院上海生命科学研究院         生物化学与分子生物学    理学博士

2006年9月-2010年7月         西北农林科技大学                             生物技术                         理学学士

研究方向

1) 免疫抑制性细胞在肿瘤微环境中的作用；2) 免疫抑制分子在白血病中的功能。

代表性论著

1. Xiaoye Liu#, Ryan Huang#, Zhiqiang Ku, Jingjing Xie, Heyu Chen, Yubo He, Qi Lou, Chengcheng Zhang, Xing Yang, Cheryl Lewis, Jade Homsi, Ankit Gupta, Lei Dong, Kenian Chen, Annabel Tu, Liming Du, Hailong Yu, Qing Hu, Meng Fang, Bufan Li, A. E. M. Adan Khan, Caroline Simith, Samuel John, Lin Xu, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang. Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer. Science Immunology. 2026;11(118):eadt7832.(#共同第一作者)

2. Ryan Huang#, Xiaoye Liu#, Jaehyup Kim, Hui Deng, Xun Gui, Heyu Chen, Guojin Wu, Wei Xiong, Jingjing Xie, Cheryl Lewis, Jade Homsi, Xing Yang, Chengcheng Zhang, Yubo He, Qi Lou, Caroline Smith, Samuel John, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang. LILRB3 supports immunosuppressive activity of myeloid cells and tumor development. Cancer Immunology Research. 2024;12(3):350–362. (#共同第一作者)

3. Xiaoye Liu#, Feifei Zhang#, Yaping Zhang#, Xie Li#, Chiqi Chen#, Meiyi Zhou, Zhuo Yu, Yunxia Liu, Yuzheng Zhao, Xiaoxin Hao, Yabin Tang, Liang Zhu, Ligen Liu, Li Xie, Hao Gu, Hongfang Shao, Fangzhen Xia, Chunrong Yin, Minfang Tao, Jingjing Xie, Cheng Cheng Zhang, Yi Yang, Haipeng Sun, Guo-Qiang Chen, Junke Zheng. PPM1K regulates hematopoiesis and leukemogenesis through CDC20-mediated ubiquitination of Meis1 and p21. Cell Reports. 2018;23(5):1461–1475. (#共同第一作者)

4. Yaping Zhang#, Fangzhen Xia#, Xiaoye Liu#, Zhuo Yu#, Li Xie, Ligen Liu, Chiqi Chen, Haishan Jiang, Xiaoxin Hao, Xiaoxiao He, Feifei Zhang, Hao Gu, Jun Zhu, Haitao Bai, Cheng Cheng Zhang, Guo-Qiang Chen, Junke Zheng. JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/β-catenin/CCND1 signaling. J Clin Invest. 2018;128(5):1737-1751. (#共同第一作者)

5. Feifei Zhang#, Xiaoye Liu#, Chiqi Chen, Jun Zhu, Zhuo Yu, Jingjing Xie, Li Xie, Haitao Bai, Yaping Zhang, Xia Fang, Hao Gu, Chun Wang, Wei Weng, Cheng Cheng Zhang, Guo-Qiang Chen, Aibing Liang, Junke Zheng. CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27kip1 signaling. Haematologica. 2017;102(4):707-718. (#共同第一作者)

6. Chengcheng Zhang, Yubo He, Xiaoye Liu, Jingjing Xie, Meng Fang, Xing Yang, Ryan Huang, Qi Lou, Bufan Li, Ankit Gupta, Cheryl Lewis, Marc I. Diamond, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang. Oligomeric cystatin C supports the immunosuppressive activity of myeloid cells through interaction with inhibitory receptors. Signal Transduction and Targeted Therapy. 2025;10:368

7. Xing Yang, Ryan Huang, Meng Fang, Yubo He, Jingjing Xie, Xiaoye Liu, Chengcheng Zhang, Qi Lou, Mi Deng, Wei Xiong, Cheryl Lewis, Zade Sadek, Ankit Gupta, Lianqi Chen, Xuewu Zhang, Lei Guo, Lin Xu, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang. Secretogranin 2 binds LILRB4 resulting in immunosuppression. Nature Immunology. 2025;26(9):1567-1580.

8. Yubo He#, Chengcheng Zhang#, Lingxiao Tan, Mi Deng, Xiaoye Liu, Ryan Huang, Xing Yang, Jingjing Xie, Qi Lou, Meng Fang, Caroline Smith, Samuel John, Wei Xiong, Xin Li, Cheryl Lewis, Jade Homsi, Ankit Gupta, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang. Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development. Cancer Immunology Research. 2025;13(6):821-835.

9. Xizhen Lian, Sumanta Chatterjee, Yehui Sun, Sean A Dilliard, Stephen Moore, Yufen Xiao, Xiaoyan Bian, Kohki Yamada, Yun-Chieh Sung, Rachel M Levine, Kalin Mayberry, Samuel John, Xiaoye Liu, Caroline Smith, Lindsay T Johnson, Xu Wang, Cheng Cheng Zhang, David R Liu, Gregory A Newby, Mitchell J Weiss, Jonathan S Yen, Daniel J Siegwart. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nature Nanotechnology. 2024；19:1409–1417.

10. Mahmoud Salama Ahmed, Ngoc Uyen Nhi Nguyen, Yuji Nakada, Ching-Cheng Hsu, Ayman Farag, Nicholas T Lam, Ping Wang, Suwannee Thet, Ivan Menendez-Montes, Waleed M Elhelaly, Xi Lou, Ilaria Secco, Mateusz Tomczyk, Lorena Zentilin, Jimin Pei, Miao Cui, Matthieu Dos Santos, Xiaoye Liu, Yan Liu, David Zaha, Gregory Walcott, Diana R Tomchick, Chao Xing, Cheng Cheng Zhang, Nick V Grishin, Mauro Giacca, Jianyi Zhang, Hesham A Sadek. Identification of FDA-approved drugs that induce heart regeneration in mammals. Nature Cardiovascular Research. 2024;3:372–388.

11. Jingjing Xie, Xun Gui, Mi Deng, Heyu Chen, Yuanzhi Chen, Xiaoye Liu, Zhiqiang Ku, Lingxiao Tan, Ryan Huang, Yubo He, Bruce Zhang, Cheryl Lewis, Kenian Chen, Lin Xu, Jian Xu, Tao Huang, X Charlene Liao, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang. Blocking LAIR1 signaling in immune cells inhibits tumor development. Frontiers in Immunology. 2022;13:996026.

12. Peng Zhao, Yuanzhong Xu, Lu-Lin Jiang, Xuejun Fan, Zhiqiang Ku, Leike Li, Xiaoye Liu, Mi Deng, Hisashi Arase, Jay-Jiguang Zhu, Timothy Y Huang, Yingjun Zhao, Chengcheng Zhang, Huaxi Xu, Qingchun Tong, Ningyan Zhang, Zhiqiang An. LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. Molecular Neurodegeneration. 2022;17:44.

13. Guojin Wu, Yixiang Xu, Robbie D Schultz, Heyu Chen, Jingjing Xie, Mi Deng, Xiaoye Liu, Xun Gui, Samuel John, Zhigang Lu, Hisashi Arase, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang. LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis. Nature Cancer. 2021;2:1170–1184.

14. Mi Deng, Heyu Chen, Xiaoye Liu, Ryan Huang, Yubo He, Byounggyu Yoo, Jingjing Xie, Samuel John, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang. Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. Antibody Therapeutics. 2021;4(1):16-33.

国际专利

Zhiqiang An, Ningyan Zhang, Zhiqiang Ku, Cheng Cheng Zhang, Xiaoye Liu, Heyu Chen, Jingjing Xie, Maria Jose Costa, An Song, X. Charlene Liao. Novel LILRB2 antibodies and uses thereof. 专利号: WO2021158413A1